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Abstract
Background: Eurycomanone is a cytotoxic compound found in Eurycoma longifolia Jack. Previous
studies had noted the cytotoxic effect against various cancer cell lines. The aim of this study is to
investigate the cytotoxicity against human hepato carcinoma cell in vitro and the mode of action.
The cytotoxicity of eurycomanone was evaluated using MTT assay and the mode of cell death was
detected by Hoechst 33258 nuclear staining and flow cytometry with Annexin-V/propidium iodide
double staining. The protein expression Bax, Bcl-2, p53 and cytochrome C were studied by flow
cytometry using a spesific antibody conjugated fluorescent dye to confirm the up-regulation of p53
and Bax in cancer cells.
Results: The findings suggested that eurycomanone was cytotoxic on cancerous liver cell, HepG2
and less toxic on normal cells Chang's liver and WLR-68. Furthermore, various methods proved
that apoptosis was the mode of death in eurycomanone-treated HepG2 cells. The characteristics
of apoptosis including chromatin condensation, DNA fragmentation and apoptotic bodies were
found following eurycomanone treatment. This study also found that apoptotic process triggered
by eurycomanone involved the up-regulation of p53 tumor suppressor protein. The up-regulation
of p53 was followed by the increasing of pro-apoptotic Bax and decreasing of anti-apoptotic Bcl-2.
The increased of cytochrome C levels in cytosol also results in induction of apoptosis.
Conclusion: The data suggest that eurycomanone was cytotoxic on HepG2 cells by inducing
apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2.
Background
Malignant tumors of the liver can be primary or second-
ary. Most of them are asymptomatic, with normal liver
function. The two commonest malignant primary tumors
of the liver are hepatocellular carcinoma (HCC) and
cholangiocarcinoma. The former is ten times commoner
than cholangiocarcinoma, and is one of the commonest
malignant primary neoplasma worldwide [1].
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HCC is the fifth commonest neoplasm in the world, and
third commonest cause of cancer-related death. More
than 500 000 new cases are diagnosed annually world-
wide. The incidence ranges from fewer than 10 cases per
100 000 population in North America and Western
Europe to 50–150 cases per 100 000 population in parts
of Africa and Asia [1]. The incidence of HCC has increased
in the last decade, reflecting the higher rates of infection
by hepatitis-C virus and improvements in the manage-
ment of cirrhosis. It is uncommon in the UK and accounts
for only 2% of cancers. There are 1500 deaths per year due
to HCC in the UK and the incidence is increasing annually
[1].
In Malaysia, approximately 1223 primary liver cancer
cases were diagnosed in the year 2000. However, it is com-
mon for cancer to spread to the liver from the colon,
lungs, breasts, or other parts of the body. When this hap-
pens, the disease is not liver cancer. The cancer in the liver
is a secondary cancer. It is named for the organ or the tis-
sue in which it began. Primary liver cancer or HCC on the
other hand, arises from the liver cells itself. HCC is very
common in the Asian region. The incidence of HCC
increases with age and it is commoner in men than in
women [2].
HCC is strongly associated with chronic liver infection or
hepatitis, especially Hepatitis B & C viruses. The high inci-
dence of chronic liver infection in Asia is the main cause
of HCC in this region. Other important risk factors
include liver cirrhosis from excessive alcohol consump-
tion as well as ingestion of aflatoxin, a substance which is
found in mouldy nuts and grain. HCC, however, is not
hereditary and therefore do not run in the families in
absence of the above risk factors [2].
The symptoms of liver cancer are often non-specific. The
diagnosis of HCC is usually confirmed by imaging and
blood tests. Imaging techniques such as ultrasound and
CT scan would usually show either a single or multiple
swellings in the liver. To confirm the diagnosis of HCC, a
tissue sample of the liver swelling can be taken by insert-
ing a needle through the skin into the liver. The biopsy
sample is then examined under the microscope to confirm
it is indeed a primary liver cancer. However, a biopsy may
not be necessary in all cases, especially when the level of
alpha feto-protein is very high [2]. At this time, no one
knows its exact causes. However, scientists have found
that people with certain risk factors are more likely than
others to develop liver cancer.
In the past decade, the role of p53 as apoptotic trigger has
been well demonstrated by both in vitro and in vivo studies
(Yu 2006). Over expression of p53 has been found in
many types of human malignancies. There is evidence that
supports the existence of a high level of p53 alterations in
HCC. At present, many studies of p53 focus on its roles in
the pathogenesis and development, diagnosis and treat-
ment, and therapeutic effects and prognosis of HCC [3-8].
Natural products are still major sources of new drug devel-
opment, for example, between 1981 and 2002, 5% of the
1031 new chemical entities approved as a drug by the US
Food and Drug Administration (FDA) were natural prod-
ucts and another 23% were natural-product-derived mol-
ecules [9]. The use of herbal medicines as alternative
medicines has become increasingly popular in Malaysia
and throughout the world. The failure of some conven-
tional medical approaches to produce positive treatment
results augments the desire to seek alternative herbal ther-
apies. In addition, herbal medicines are perceived by the
public to have lesser side effects as compared to allopathic
medicine. Many people are turning back to natural reme-
dies, especially herbal medicine as a solution for main-
taining health and for the treatment of disease. In
Malaysia, one of the most popular herbs is Eurycoma longi-
folia. E. longifolia (Simaroubaceae) is one of the most well
known folk medicines for intermittent fever (malaria) in
Southeast Asia including Myanmar, Indochina, Thailand,
Laos, Cambodia and Malayaia [10-13]. E. longifolia, a
plant in the family simaroubaceae is a tall slender shrub-
tree commonly founds as an understorey in the lowland
forests up to 500 m above sea level [11].
In Malaysia, E. longifolia is identified locally as 'Tongkat
Ali', 'Pasak Bumi' or 'Bedara Pahit' in Indonesia 'Ian-don'
in Thailand [11,13,14]. In Vietnam, E. longifolia is named
'Cay ba binh' translated as 'a tree which cures hundreds of
disease' [15]. The roots of this plant are used as folk med-
icine for treatment of aches, persistent fever, tertian
malaria, sexual insufficiency, dysentery, glandular swell-
ing and as a health supplements [16]. From the roots, sev-
eral classes of compounds have been identified and they
included quassinoids, canthin-6-one alkaloids, β-carbo-
line alkaloids, tirucallane-type triterpenes, squalene deriv-
atives and biphenylneolignans. Some of these
constituents were shown to possess cytotoxic, antimalar-
ial, antiulcer, antipyretic and plant growth inhibition
activities. The quassinoids 14,15 beta-dihydroxyklaine-
anone inhibited tumor promoter-induced Epstein-Barr
virus activation at an in vitro [17]. Two quassinoids, pasak
bumi A (also known as eurycomanone) and pasak bumi
B exhibited antiulcer activity [18]. Eurycomanone have
shown the great anticancer activities towards the leukemia
cells, KB IV and P388. The previous studies also reported
that Eurycomanone have a cytotoxic effects on colon can-
cer, breast cancer, lung cancer, skin cancer (melanoma),
fibrosarcoma and lung cancer [19]. Hence, this finding
may show that E. longifolia have a potential to be a new
active drug for cancer suppression.Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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Previous study of methanolic extract showed induction of
apoptosis in human breast cancer MCF-7 cell lines via
decreasing of Bcl-2 expression [20-26]. Eurycomanone
isolated from E. longifolia was also proven to inhibit the
growth of MCF-7 cells by triggering apoptosis through
down-regulation of the anti-apoptotic protein Bcl-2. It is
relatively non-toxic in non-cancerous breast cell lines
(MCF-10A)[20]. Eurycomanone also showed the antipro-
liferative effect in human cervical carcinoma, Hela cells
and induces apoptosis through the up-regulation of
p53[21].
Strategies to develop chemopreventive drugs for use have
been evolving for many years [9,22]. Recently, considera-
ble emphasis has been placed on identifying new cancer
chemopreventive compounds capable of inhibiting,
retarding or reversing the multistage carcinogenesis. How-
ever, the potential use of plants as a source of new drug is
still poorly explored. The aim of this study is to isolate and
purified Eurycomane, an active compound from the roots
of Eurycoma longifolia and examine the cytotoxic effect in
human hepatoma cells, HepG2 and determine the mode
of action for the compound in induces cell death.
Methods
Plant materials
The dried roots of E. longifolia were provided by Prof Dr
Azimahtol Hawariah Lope Pihie (National University of
Malaysia, Malaysia).
Extraction and isolation of the compound
The dried roots (500 g) of E. longifolia were extracted with
methanol under reflux (60°C, 48 hours) and concen-
trated using rotary evaporator to give dark brown syrup.
The methanol extract was partitioned with diethylether
(Et2O) saturated with water. The aqueous soluble portion
was further partitioned with n-butanol (BuOH) and water
(1:1). The BuOH extract was subjected to column chroma-
tography on silica gel column and eluted with ethyl ace-
tate (EtOAc); ethanol (EtOH); water (H2O) (100:10:1).
Fractions were collected, checked by preparative Thin
Layer Chromatoghraphy (TLC) using 20% methanol in
chloroform as an eluent to give 6 partially purified frac-
tions (F16–F21) of eurycomanone. Fractions contained
eurycomanone were further analyzed by High Perform-
ance Liquid Chromatography (HPLC).
Cell culture
HepG2, HM3KO, CaOV3, Hela, CCD11114sk and
Chang's liver cells were obtained from the American Type
Culture Collection (ATCC, Manassas, Virginia, USA).
Cells were maintained in Dulbecco's modified eagle's
medium (DMEM; Invitrogen Co., Carlsbad, California,
USA) supplemented with 10% heat-inactivated fetal calf
serum (Invitrogen Co.), 100 U/ml penicillin and 100 mg/
ml streptomycin (Flowlab, Sydney, Australia) in a humid-
ified atmosphere of 5% CO2 in air at 37°C. Cells were
kept in the logarithmic growth phase by routine passage
every 2–3 days using 0.025% trypsin-EDTA treatment.
Cell proliferation assay
The antiproliferative activity was evaluated by using the
MTT method as previously described, with some modifi-
cations [23]. Briefly, cells were seeded 24 hours prior to
treatment in a 96-well plate at 5 × 104 cells/well in order
to obtain 70% to 80% confluent cultures. Before addition
to the culture medium, the crude extract of E. longifolia
was dissolved in water and eurycomanone was dissolved
in DMSO (Sigma Chemical Co., St. Louis, Missouri, USA)
and followed by a 2× serial dilution for 10 points ranged
from 0.2 μg/ml to 100 μg/ml. The final concentration of
DMSO used in the corresponding wells did not exceed 1%
(v/v). This concentration of DMSO does not effects cell
viability [18]. Control cultures received the same concen-
tration of solvent alone and tamoxifen (Sigma Chemical
Co.) was used as a positive control. The 96-well plate was
incubated for 72 hours at 37°C in a humidified atmos-
phere with 5% CO2. At the end of incubation, 50 ul of
MTT solution (2 mg/ml MTT in plain culture medium;
Sigma Chemical Co.) was added to each well. The plate
was then incubated for 4 hours. MTT solution was
removed and the purple formazan crystal formed at the
bottom of the wells was dissolved with 200 μl DMSO for
20 minutes. The absorbance at 570 nm was read on a
spectrophotometric plate reader (Thermo Electron Co.,
Waltham, Massachusetts, USA). The proportion of surviv-
ing cells was calculated as (OD of drug-treated sample –
OD of blank)/(OD of control – OD of blank) × 100%.
Dose-response curves were constructed to obtain the IC50
values. All experimental data were derived from at least 3
independent experiments.
Hoechst 33258 nuclear staining assay
Nuclear staining with Hoechst 33258 (Sigma Chemical
Co.) was performed as described elsewhere [17,18,24].
Briefly, the floating and trypsinized-adherent of treated
and non-treated cells were collected and washed with PBS.
The cells were then fixed with 4% paraformaldehyde in
PBS for 30 minutes at 4°C. After washing, the cells were
smeared onto microscope slides followed by incubation
in Hoechst 33258 at a final concentration of 30 μg/ml at
room temperature for 30 minutes. Nuclear morphology
was then examined under a fluorescent microscope
(Imaging Source Europe GmbH, Bremen, Germany).
Cell cycle analysis
HepG2 cells were grown in 25 cm2 culture flasks under a
humidified 5% CO2 atmosphere at 37°C. The seeding
density was 5 × 104 cells/ml. Flasks were pre-incubated for
overnight before the solutions of drugs or control wereCancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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added to each flask. Vinblastine sufate (2.5 mg/ml) was
used as a positive control and negative control received
only DMSO. The concentration of eurycomanone used in
this experiment was 5 μg/ml. After a period of exposure
(24, 48 and 72 hours), cells were harvested by trypsiniza-
tion with trysin/EDTA solution (Sigma-Aldrich, T4049),
collected and fixed in ice-cold 70% ethanol for at least 1 h
at 4°C. Cell pellet were resuspended with 0.9 ml 1% Tri-
ton X-100 in PBS and 100 μl of 1 mg/ml RNase A (Sigma-
Aldrich, R5500). The solution was incubated for 30 min-
utes at 37°C. Cells were stained with 100 μl of 10 μg/ml
PI (Sigma-Aldrich, P4170) solution in staining buffer (1%
Triton-X 100 in PBS) and protected from light. Stained
cells were incubated at room temperature (RT) for 30
minutes. Samples were then put back in ice and 300 μl of
staining buffer and analyzed using a Beckman-Coulter
FACS Calibur-500 flow cytometry (FCM).
Apoptosis measurement by flow cytometry
The number of apoptotic cell death induced by eury-
comanone was measured by flow cytometry using the BD
Pharmingen™ annexin V-FITC, BD 556420 kit. The treated
and untreated HepG2 cells were harvested and washed
with cold PBS. The cell pellet was re-suspended in 1×
binding buffer at a concentration of 1 × 106 cells/ml. 100
μl of cell suspension was transferred into FCM tube. 5 μl
of Annexin V-FITC and 5 μl of PI were added into the cell
suspension, followed by gentle vortexing. The staining
samples were incubated for 15 minutes at room tempera-
ture (RT) in darkness. An additional 400 μl of 1× binding
buffer was added to each tube. Samples were analysed by
Beckman-Coulter FACS Calibur-500 flow cytometry
within 1 hour. 100 000 events was acquired using green
channel FL1 for Annexin V-FITC and the red channel FL3
for PI.
Detection of proteins involve in apoptosis (Bcl-2; Bax; p53; 
Cytochrome C)
Cells were cultured in 25 cm2 culture flasks (5% CO2,
37°C) at seeding density of 5 × 104 cells/ml. Plates were
pre-incubated overnight before the solutions of drug were
added to each well. After a period of exposure (24, 48 and
72 hours), cells were harvested by trypsinization with
trypsin/EDTA solution and centrifuged at 1800 rpm. Cells
were washed twice with 1× PBS and then were fixed with
ice-cold 70% ethanol (≤ 1 hour, 4°C), washed twice with
1× PBS and re-suspended in blocking buffer (2% BSA) for
10 minutes, followed by another washing step. Cells pel-
let were re-suspended in PBS to a concentration 1 × 107
cells/ml and 100 μl of cells suspension (1 × 106 cells/ml)
were transferred into each sample tube and 20 μl of FITC/
PE conjugated antibody were added into tubes followed
by gently mixed. The antibodies used in this experiment
are: FITC-conjugated Bcl-2 antibody (BD Pharmingen);
PE-conjugated Bax antibody (Santa Cruz Biotechnology,
Inc.); PE-conjugated p53 antibody (BD Pharmingen);
FITC-conjugated Cytochrome C antibody (Santa Cruz
Biotechnology, Inc.). The tubes were incubated at RT for
20 – 30 minutes in the dark. The pellets were washed with
2 ml of 1× PBS and the supernatant were aspirated. Cell
pellets were re-suspended in 500 μl of 1× PBS and ready
to proceed for FCM analysis (Beckman-Coulter FACS Cal-
ibur-500)
Statistical analysis
All values are expressed as the mean ± S.D. Statistical anal-
yses were evaluated by Student's t-test. Probability values
p < 0.05 were considered statistically significant.
Results
Effect of eurycomanone on cell viability
The anti-proliferative activity of E. longifolia will be
assessed from its IC50 on various cell lines. The aim of pre-
liminary screening was to select the most effective sup-
pression of cell growth against E. longifolia treatment.
Because of the limited time and financial support for
present study, only the cell line which showed most effec-
tive inhibition by the extract was selected for further work.
Results from the preliminary assay for cytotoxic activity of
E. longifolia crude extract were evaluated by obtaining the
IC50 values as in figure 1a. IC50 value is an effective dose
required to inhibit the proliferative response by 50%.
Onset of action and the percentage survival of cells have
been taken into consideration in order to categories the
potency of the crude extract. In the US NCI plant screen-
ing program, a crude extract is generally considered to
have in vitro cytotoxic activity if the concentration that
causes a 50% cell kill (in KB carcinoma cells) is less than
20 μg/ml and less than 4 μg/ml for the pure compound,
following incubation between 48–72 h [25]. In this study,
this value was used as a rough reference point for assessing
the activity of the natural agent used.
Within the four cancer cell lines used in this experiment,
crude extract of E. longifolia was more effective against
HepG2 cells with IC50 45 ± 0.15 μg/ml. Both HM3KO and
Hela cells gave an IC50 value of 60 ± 0.25 μg/ml. For the
CaOV3 cells, the IC50 obtained was 79 ± 0.16 μg/ml.
Tamoxifen, a standard therapeutic drug used as a positive
control in this experiment showed a great toxicity towards
all the cancer cell lines used. Tamoxifen have been studied
intensely particularly on the breast cancer and it was
approved by FDA for reducing the incidence of breast can-
cer. As we can see from the graph in figure 1b, tamoxifen
show very low IC50 values with 3.7 ± 0.28 towards HepG2
cells and 2.3 ± 0.23 towards HM3KO cells. The IC50 values
for Hela cells and CaOV3 cells were 2.7 ± 0.18 and 2.1 ±
0.32 respectively.Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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Dose-response curve of E. longifolia crude extract and Tamoxifen against malignant cells (HM3KO, Hela, HepG2 and CaOV3)  and non-malignant cells (CCD11114sk and Chang's liver) Figure 1
Dose-response curve of E. longifolia crude extract and Tamoxifen against malignant cells (HM3KO, Hela, 
HepG2 and CaOV3) and non-malignant cells (CCD11114sk and Chang's liver). E. longifolia crude extract showed a 
higher toxicity towards HepG2 cells compared to the other cell lines used in the experiment. Non-malignant cells, Chang's 
Liver and CCD11114sk were not significantly affected by the crude extract and no IC50 was evident (a). Tamoxifen showed a 
cytotoxic effects on all of the cell lines used in the experiment including non-malignant cells, Chang's liver and CCD11114sk 
(b). The values of graph represent mean ± S.D of three independent experiments. P < 0.05.

b Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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However, when compared to E. longifolia crude extract,
tamoxifen not only toxic against malignant cells but also
toxic towards non-malignant cell, Chang's liver and
CCD1114sk. Tamoxifen gave an IC50 value of 2.8 ± 0.21
against CCD11114sk and 1.4 ± 0.31 towards Chang's liver
cells displaying the somewhat non-selective cytotoxicity
of tamoxifen. In contrast to tamoxifen, no anti-prolifera-
tive effect observed in both non-malignant cells. No IC50
was recorded.
The antiproliferative assay showed a great inhibitory effect
of eurycomanone towards HepG2 cells. Eurycomanone as
shown in figure 2a, significantly reduced the viability of
HepG2 cells by 50% inhibition at 3.8 ± 0.12 μg/ml. When
compared to control drug, tamoxifen which is a standard
chemotherapeutic drug, the values of IC50 for both (eury-
comanone and tamoxifen) were very close together.
Tamoxifen inhibited HepG2 cells at IC50 value of 3.7 ±
0.28 μg/ml. Eurycomanone treatment did not exhibit any
cytoselectivity towards normal liver cells, Chang's Liver
which gave IC50 of 17 ± 0.15 μg/ml. The non-cytoselectiv-
ity effect was similar to the treatment with Tamoxifen.
However, Tamoxifen is more cytotoxic towards normal
liver cells which inhibit 50% cells viability at 1.4 ± 0.31
μg/ml. As compared to Tamoxifen, Eurycomanone was 12
times less toxic against normal liver cells.
Another non-malignant human liver cell, WLR-68 also
used in this experiment as a negative control. Interest-
ingly, the results showed that eurycomanone less toxic
towards WLR-60 cells with IC50 20 ± 0.22 μg/ml (figure
2b). As compared to vinblastine sulfate, this compound
showed a highly toxicity towards, normal liver cell WLR-
68 with IC50 of 4.2 ± 0.37 μg/ml was detected. This finding
also supported that eurycomanone have less cytotoxic
effect, which mean that the compound highly toxic
toward malignant cells but not in normal cells.
Morphology of apoptosis by Hoechst staining
The mode of killing induced by most anticancer agents is
by which apoptotic cell death and DNA fragmentation is
a hallmark of apoptotic cells [26]. To further examined
the morphological changes in responds to eurycomanone
treatment, both control and eurycomanone-treated cells
were stained with fluorescent dye Hoechst 33528 and vis-
ualized under a fluorescent microscope. Hoechst nuclear
staining binds to the AT rich regions of double stranded
DNA and exhibits enhanced fluorescence.
The Hoechst dye was able to diffuse through intact mem-
branes of HepG2 cells and stain their DNA. Figure 3
showed the results of Hoechst staining for the eury-
comanone treated-HepG2 at 24, 48 and 72 hours. The
untreated HepG2 cells remained uniformly stained.
HepG2 cells show that no fluorescence was detected in the
nucleus, as the cells were not apoptotic and did not
exhibit DNA fragmentation. At 24 hours treatment, cells
began to display apoptotic morphology. Fluorescence was
detected in the nuclear region of the HepG2 cells, indicat-
ing the presence of DNA fragmentation. Enucleation and
apoptotic bodies can be seen as small fluorescent masses.
At 48 hours, nuclear condensation and fragmentation was
more apparent. The chromatin is condensed into lumps,
exhibiting punctuated morphology typical of apoptotic
cells, whereas at 72 hours, apoptotic events culminated in
the formation of apoptotic bodies, seen as smaller intense
spots. Shrinkage of cells, DNA condensations, nuclear and
plasma membrane convulsion and nuclear fragmentation
were all observed in treated cells. Positive control of
tamoxifen-treated cells displayed similar nuclear fluores-
cence indicating that the data obtained can be accepted.
These observations provide evidence that an apoptotic
pathway is occurring with the eurycomanone treatment.
Eurycomanone-arrested cell cycle at G2/M phase
The antiproliferative activity displayed by eurycomanone
may be by a selective cytotoxic manner. A wide variety of
agents trigger growth arrest as well as cell death [27].
Many reports indicate that cell cycle arrest leads to cell
growth inhibition or apoptosis. Cell cycle arrest is a good
marker for chemopreventive or anti-tumor activity of
chemicals or drugs [28]. However, no reports to show a
checkpoint for the cell cycle arrest towards HepG2-treated
eurycomanone. Therefore, further investigated the natures
of cell cycle progression in HepG2 cells under eury-
comanone treatment using a flow cytometer approach
were done. The cell cycle distribution was examined at
various times and indicated doses. Vinblastine sulfate was
used as a positive control.
As shown in figure 4, cells under normal conditions
(untreated) showed the expected pattern for continuing
growing cells by which the highest peak in the region of
G1 phase and a small low peak in G2/M phase. The
number of cells count was calculated and presented in a
graph in figure 5. There were no significant differences
within the G1 peak for untreated cells at 24 and 48 hours
with percentage cell count of 72.5% and 73.6%, respec-
tively (figure 5a). Besides, at 72 hours of treatment dura-
tion, a bit decreased of cells population to 67.5% was
observed. Maybe, it is because of the normal process for
the cells to go apoptosis following increasing time of incu-
bation. However, most of the cells accumulated at G1
phase.
Cells treated-eurycomanone showed an accumulation in
G2/M phase following 48 hours of exposure with 20.8%
of the cells population compared to 24 hours with
16.58% (figure 5b). At 72 hours, the significantly
increased percentage of cells in G2/M phase was observedCancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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Dose-response curve of eurycomanone, tamoxifen and vinblastine sulfate against HepG2 cells and WLR-68 Figure 2
Dose-response curve of eurycomanone, tamoxifen and vinblastine sulfate against HepG2 cells and WLR-68. 
Eurycomanone and tamoxifen signifcantly shown a reduced the number of viable malignant HepG2 cells and non-malignant 
Chang's Liver cells in a dose dependent manner (a). Eurycomanone and vinblastine sulfate also signifcantly shown a reduced the 
number of viable non-malignant WLR-68 cells in a dose dependent manner (b). The values of graph represent mean ± S.D of 
three independent experiments. P < 0.05.
a 

 b Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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Nuclear staining of HepG2 cells with Hoecsht 33258 Figure 3
Nuclear staining of HepG2 cells with Hoecsht 33258. Cells were treated with eurycomanone and control drug, 
tamoxifen. (a) Untreated (control) HepG2 cells remained uniformly stained with round and unpunctuated nucleus. (b) 
Tamoxifen-treated HepG2 at 24 hours. (c) Tamoxifen-treated HepG2 at 48 hours. (d) Tamoxifen-treated HepG2 at 72 hours. 
(e) Eurycomanone-treated HepG2 at 24 hours. (f) Eurycomanone-treated HepG2 at 48 hours. (g) Eurycomanone-treated 
HepG2 at 72 hours. Eurycomanone-treated HepG2 cells showed apoptotic morphology; cell shrinkage, DNA condensation 
and nuclear fragmentation as for tamoxifen.
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DNA content of HepG2 cells detected by flow cytometry Figure 4
DNA content of HepG2 cells detected by flow cytometry. Untreated HepG2 cells (purple square); HepG2-treated 
eurycomanone (red square) and HepG2-treated vinblastine sulfate (orange square); for 24, 48 and 72 hours (a). A = G0 phase; 
B = G1 phase; C = S phase; D = G2/M phase. Untreated cells showed the highest peak in the region of G1 phase and a small 
low peak in G2/M phase. HepG2 cells treated with eurycomanone increased at G2/M peak suggested that, eurycomanone 
arrested HepG2 cell cycle at G2/M phase. Following vinblastine treatment, as a control drug, the G2/M peak dramatically 
increased. The significant accumulation of cells clearly indicates that vinblastine sulfate efficiently arrested the cell cycle 
progress in HepG2 cells at the G2/M phase.
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Graph summarized the DNA contents of HepG2 cells for the various treatments Figure 5
Graph summarized the DNA contents of HepG2 cells for the various treatments. Untreated HepG2 cells (B); 
HepG2-treated eurycomanone (b) and HepG2-treated vinblastine sulfate (c). The values of the bars represented mean ± S.D. 
of three independent experiments. P < 0.05.
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with 39.9% of cells accumulated was recorded. Along with
decreasing of G2/M phase, a dramatically decreased of
HepG2 cells population in G1 phase were detected with
percentage of 59.9% at 24 hours to 55.4% at 48 hours and
39.9% at 72 hours. This finding suggested that eury-
comanone inhibited the cell proliferation by inducing the
G2/M arrest in a time-dependent manner in HepG2 cells
through regulating the G2 checkpoint.
The amount of apoptotic cells was calculated based on the
appearance of cells in G0. G0 phase is corresponds to
apoptotic cells. Although there was an increase of apopto-
sis in eurycomanone-treated cells, the magnitude of
change was relatively small in comparison to the growth
inhibition. Distribution of the G2/M phase cells in the
population increase while the percent of apoptotic cells
rose from 3.5% to 10.4%. This is also evident that the G2/
M phase became the dominant phase in cells treated with
5 μg/ml of eurycomanone in a time-dependent manner
with a late apoptosis. These finding indicate that at the
ranges of concentration studied, the antiproliferative
effect of eurycomanone on HepG2 cells could be attrib-
uted primarily to the induction of G2/M arrest, with less
contribution of cell division rather than DNA synthesis.
Following vinblastine sulfate treatment (figure 5c), which
is a control drug, the G2/M peak dramatically decreased
cell population of G1 phase (2.5%) and increased per-
centage of cells in G2/M phase (80.7%) at 24 hours expo-
sure compared to control. Therefore, at 48 h of treatment,
G2/M phase decreased to 49.1%, along with increased of
G0 phase from 10.6% at 24 hours to 17.7%. Notably,
maximal G2/M phase arrest by vinblastine sulfate admin-
istration was observed at 24 hours and at 72 hours for
eurycomanone. The significant accumulation of cells
clearly indicates that vinblastine sulfate efficiently
arrested the cell cycle progress in HepG2 cells at the G2/M
phase. This result is consistent with those in the literature
[29] and testifies that the established cell cycle analysis
protocol with HepG2 cell line was working properly in the
present work.
Eurycomanone-induced apoptotic cell death
To further confirm that eurycomanone induces cell apop-
tosis, HepG2 cells were stained with annexin V-FITC and
PI, and subsequently analyzed by flow cytometry (FCM).
As indicated in figure 6a, in untreated cells only 0.3% of
HepG2 cells were annexin V+/PI-, indicating the apoptotic
cells, whereas 0.58% of the cells were double positive (late
apoptotic cells) at 24 hours of incubation time. The apop-
totic cells showed a bit increased after 48 hours treatment
with 0.69% and late apoptotic cells with 0.95%. At 72
hours of treatment duration, only 6.4% of apoptotic cells
were detected with 0.04% of late apoptotic cells. Most of
the cells for all treatment duration (24, 48 and 72 hours)
were still viable with percentage of 97.43%, 95.9% and
93.6%, respectively (figure 6b). This result significantly
showed that in untreated HepG2 cells, cells continuously
growth and an apoptosis process just appeared as a nor-
mal process in every cell lives. Results also supported the
finding from the analysis of DNA contents which previ-
ously reported in this study.
After treatment with eurycomanone (figure 7a) for 24
hours, apoptotic cells increased to 32.97% along with
decreased in viable cells to 65.36%. Following exposure
for 48 hours, annexin V+ quadrant dramatically increase to
80.5% and late apoptotic cells also increased with 12.10%
were detected. Viable cells decreased to 10.0%. However,
at 72 hours of treatment, only 74.1% of the cells were
detected in quadrant of annexin V+/PI-, but the increased
of cells population were observed at late apoptotic quad-
rant with percentage of 15.3%. Eurycomanone was
showed to induce apoptosis in HepG2 cells in a time-
dependent manner. After 72 hours of exposure, only 5.6%
cells were alive indicating that almost all of cells undergo
apoptosis (figure 7b). This data confirm that eury-
comanone was capable of inducing cell death in HepG2
cells and suggested that the mechanism of cell death in
HepG2-treated eurycomanone was via apoptosis process.
According to Nurkhasanah et al. 2008, after exposure of
Hela cells with eurycomanone, the level of apoptotic cells
in annexin +/PI- quadrant was increased at 24 and 48
hours, thus indicating that eurycomanone induced apop-
tosis in Hela cells. Some of natural resources also reported
to induce apoptosis in HepG2 cells such as solanine or
Solanum nigrum Linn [30] and apigenin [31].
Vinblastine sulfate used as a positive control in this
present experiment. Vinblastine sulfate showed a decreas-
ing number of viable cells with increasing time of incuba-
tion (figure 8a). At 24 hours, percentage of cells
population in double negative quadrant was 57.84% and
decreased to 25.1% at 48 h and 10.3% at 72 hours. Inter-
estingly, at 72 hours, late apoptotic cells greatly increased
to 69.8% along with 17.0% of apoptotic cells compared to
percentage of 46.2% at 48 hours and 40.47% at 72 hours
with late apoptotic of 24.2% and 0.38%, respectively (fig-
ure 8b). This data have similarity with the results of DNA
contents for cell cycle analysis which mentioned above.
Eurycomanone-induced p53 and Bax up-regulation
To investigate the intracellular mechanism for the
observed increase in apoptosis in eurycomanone-treated
HepG2 cells, the expression of the pro- apoptotic Bax and
anti-apoptotic Bcl-2 proteins will be studied. Also, the
involvement of the tumor suppressor protein p53 will be
determined along with cytochrome C release. Protein lev-
els discerned from treated and non-treated cells will then
be quantitated and compared to observe possible modu-Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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Scatter plots of Ann/PI-untreated HepG2 cells under four situations in quadrant analysis Figure 6
Scatter plots of Ann/PI-untreated HepG2 cells under four situations in quadrant analysis. They are living cells 
(A3), apoptotic cells (A4), late apoptotic or dead cells (A2) and necrotic or dead cells (A1). Exposed for 24 hours (1); exposed 
for 48 hours (2); exposed for 72 hours (3)(a). The graph summarized the number of cells in each quadrant (b). The values of 
the bars represented mean ± S.D. of three independent experiments. P < 0.05.
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Scatter plots of Ann/PI-stained HepG2 cells treated-eurycomanone (5 μg/ml) under four situations in quadrant analysis Figure 7
Scatter plots of Ann/PI-stained HepG2 cells treated-eurycomanone (5 μg/ml) under four situations in quadrant 
analysis. They are living cells (A3), apoptotic cells (A4), late apoptotic or dead cells (A2) and necrotic or dead cells (A1). 
Exposed for 24 hours (1); exposed for 48 hours (2); exposed for 72 hours (3)(a). The graph summarized the numbers of cells 
in each quadrant (b). The values of the bars represented mean ± S.D. of three independent experiments. P < 0.05.
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Scatter plots of Ann/PI-stained HepG2 cells treated-vinblastine sulfate (2.5 μg/ml) under four situations in quadrant analysis Figure 8
Scatter plots of Ann/PI-stained HepG2 cells treated-vinblastine sulfate (2.5 μg/ml) under four situations in 
quadrant analysis. They are living cells (A3), apoptotic cells (A4), late apoptotic or dead cells (A2) and necrotic or dead cells 
(A1). Exposed for 24 hours (1); exposed for 48 hours (2); exposed for 72 hours (3)(a). The graph summarized the numbers of 
cells in each quadrant (b). The values of the bars represented mean ± S.D. of three independent experiments. P < 0.05.
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lation by eurycomanone. Flow cytometry approach was
used to detect the levels of proteins with specific antibody
conjugated-FITC (fluorescein isothiocyanate) and PE
(phycoerythrin).
The analysis of the effect of eurycomanone on the expres-
sion of Bcl-2 protein in HepG2 cells using flow cytometry
shows that eurycomanone can inhibit Bcl-2 activity as the
time of exposure increases. The expression of Bcl-2 pro-
tein is lower as shown in figure 9b compared to the
untreated HepG2 cells (figure 9a). In untreated HepG2, a
great accumulation of Bcl-2 proteins were observed. At 24
hours of treatment duration, 98.3% of Bcl-2 was detected
and no significant increases for the other proteins, Bax,
p53 and cytochrome C. Following treatment at 48 h and
72 hours, the Bcl-2 levels slowly decreased to 86.0% and
81.5%, respectively (figure 10a). Furthermore, the expres-
sion of Bax protein have been seen to increase but only in
a small value which is 0.7% at 48 hours to 3.1% at 72
hours.
HepG2 treated-eurycomanone inhibited the expression
levels of Bcl-2. On the contrary from untreated cells, at 24
hours of exposure with eurycomanone, Bcl-2 levels dra-
matically decreased to 14.9% and again, at 48 hours, the
levels decreased to 6.9% and only 1.8% after 72 hours of
treatment. The accumulation of Bax proteins were signifi-
cantly occurred (figure 10b). The percentage of 79.1% of
Bax proteins were calculated at 24 hours of incubation
with eurycomanone. The expression levels of Bax
increases in a time dependent. At 48 hours, the Bax pro-
teins increased to 88.5% and further increased to 92.3%.
These results also supported by the previous studied
which shows that eurycomanone suppressed the levels of
Bcl-2 proteins and increased the expression levels of Bax
in Hela cells (Nurkhasanah et al. 2008).
As for in HepG2 treated-vinblastine sulfate, Bcl-2 levels
also inhibit in a time dependent manner. From 27.3% at
24 hours, the expression levels of Bcl-2 decreased to
23.7% and greatly reduced to 4.1% at 74 hours. The levels
of Bax proteins also dramatically increased. The expres-
sion levels of 55.8% and 89.1% were detected at 24 and
48 hours, respectively. The expression levels showed a
maximal value at 72 hours with percentage level of 95.6%
(figure 10c).
p53 protein was detected to increase from 24 to 72 hours
of exposure, thus recommended that eurycomanone
induces apoptosis dependent p53 pathway. As shown in
figure 9c, eurycomanone triggered strong p53 protein
expression in HepG2 cells with 78.5% of p53 proteins lev-
els were expressed at 24 hours of exposure and at 48
hours, the expression level increase to 84.9% and 95.3%
at 72 hours. Along with decreasing of p53 levels, cyto-
chrome C also increased in a time dependent manner (fig-
ure 9d). The percentage of 74.4% was determined at 24
hours of treatment and 86.1% at 48 hours. At 72 hours,
the level of cytochrome C proteins showed a maximal
value of 95.5%.
Furthermore, a different pattern of HepG2-treated vin-
blastine sulfate was observed in the level of p53 proteins
and cytochrome C. As we can see from the figure 10c,
there were no significant increased in a level of p53 in
HepG2 cells treated-vinblastine sulfate for all treatment
durations. These results show that, vinblastine sulfate
enhances apoptosis in HepG2 cells via a p53-mediated
pathway. However, the expression levels of cytochrome C
were increased from 76.6% at 24 hours to 85.6% and
92.8% at 48 and 72 hours, respectively.
Discussion
Plants have formed the basis of sophisticated traditional
medicine systems among which are Ayuverdic, Yunani,
Chinese amongst others. These systems of medicine have
given rise to some important drugs still in use today [32].
Plants also are valuable source of new natural products.
Despite the availability of different approaches for the dis-
covery of therapeuticals, natural products still remain one
of the best reservoirs of new molecules [33]. The search for
new molecules, nowadays, has taken slightly different
route where the science of ethnobotany and enthnophar-
macognosy are being used as guide to lead the chemist
towards different sources and classes of compounds. Nat-
ural products play an important role in chemotherapy,
having contributed considerably to approximately 60
available cancer chemotherapeutic drugs [34]. The need
to develop more effective antitumor drugs has prompted
investigators to explore new sources of pharmacologi-
cally-active compounds, especially from natural products
[35].
Eurycomanone found in E. longifolia is one of the novel
compounds with promising potencies to be developed as
a new chemotherapeutic agent. In this study, it was found
that eurycomanone exerted anti-proliferative activity in
HepG2 cells with an IC50 value of 3.8 ± 0.12 μg/ml. Previ-
ous study of eurycomanone on Hela cells and MCF-7 cells
also showed the apoptotic effect [21,36]. This fact
increases evidence that chemotherapeutic agents induce
cancer cell death through the mechanism of apoptosis
[37]. Additionally, cytotoxicity results show that eury-
comanone gave an IC50 of 17 ± 0.15 μg/ml towards nor-
mal liver cells, Chang's Liver compared to tamoxifen with
very low IC50 value (1.4 ± 0.31 μg/ml). It is showed that
eurycomanone more selective than tamoxifen. This kind
of cytoselectivity may reduce a side effect which com-
monly occurred during chemotherapy. This finding may
lead to develop a new drug as an alternative medicine toCancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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The histogram of proteins expression detected by flow cytometry with a specific antibody Figure 9
The histogram of proteins expression detected by flow cytometry with a specific antibody. The profile of Bcl-2 
expression proteins (a); the profile of Bax expression proteins (b); the profile of p53 expression proteins (c); the profile of 
cytochrome C expression proteins (d), for 24, 48 and 72 hours. (Black square = unstained HepG2 cells; Blue square = 
untreated HepG2 cells; Red square = HepG2 cells treated-eurycomanone; Yellow square = HepG2 cells treated-vinblastine 
sulfate).
  
     




 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                         
￿
￿
￿

￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿

￿ 
￿

￿ 
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
Page 17 of 21
(page number not for citation purposes)
Graphs summarized the expression levels of Bcl-2, Bax, p53 and Cytochrome C Figure 10
Graphs summarized the expression levels of Bcl-2, Bax, p53 and Cytochrome C. a = untreated HepG2 cells; b = 
HepG2 cells treated-eurycomanone; c = HepG2 cells treated-vinblastine sulfate. The values of the bars represented mean ± 
S.D. of three independent experiments. P < 0.05.
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treat liver cancer. The previous study also showed the min-
imum effect of eurycomanone on noncancerous MDBK
and Vero cells [21] and also noncancerous breast cells
(MCF-10A) [36].
Based on the result of Hoechst staining, it was found that
treatment with eurycomanone induced DNA fragmenta-
tion in HepG2 cells. Internucleosomal DNA fragmenta-
tion is the primary biochemical characteristic to indicate
an early event of apoptosis and it represents a point of no
return from the path to cell death [38]. Shrinkage of cells,
DNA condensations, nuclear and plasma membrane con-
vulsion and nuclear fragmentation were all observed in
HepG2 cells treated-eurycomanone. Positive control of
tamoxifen-treated cells displayed similar nuclear fluores-
cence indicating that the data obtained can be accepted.
These observations provide evidence that an apoptotic
pathway is occurring with the eurycomanone treatment.
The term of 'apoptosis' was introduced into modern sci-
ence by Kerr et al. in 1972 [26] to describe the special mor-
phology of physiological cell death. The word itself is an
ancient Greek word meaning the 'falling off' of leaves
from a tree or petal from a flower and was originally used
in medical and philosophical writings of classical Greek
and Roman times. Apoptosis or programmed cell death
represents the regulated activation of a pre-existing death
program encoded genome [39,40]. Apoptosis has been
shown as a significant way of cell death after cytotoxic
drug treatment in a variety of cancer types. The induction
of apoptosis has been recognized as a strategy for the iden-
tification of anticancer drugs [41]. There is substantial evi-
dence that alteration in the cellular and molecular
pathways that control the cell cycle and apoptosis may
change the sensitivity and resistance to anticancer agents
[42].
There is an increasing realization that chemotherapeutic
agents act primarily by inducing cancer cell death through
the mechanism of apoptosis [43]. In the present study, we
provide evident eurycomanone is able to induce apopto-
sis in the human liver cancer cell line, HepG2. The mor-
phology changes took place in HepG2 cells exposed to E.
longifolia extract and eurycomanone. When stained with a
Hoechst nuclear fluorochrome, the chromatin of the eury-
comanone-treated HepG2 cells can be seen as condensed
into lumps, thus exhibiting the punctuated morphology
typical of apoptotic cells. The ability of eurycomanone to
inhibit cancer cells proliferation and induce apoptosis fur-
ther purports it as a potential anticancer agent in liver car-
cinomas, thus making it a promising agent for
chemotherapy, which merits further study.
The amount of apoptotic cells was calculated based on the
appearance of cells in G0. G0 phase is corresponds to
apoptotic cells. Although there was an increase of apopto-
sis in eurycomanone-treated cells, the magnitude of
change was relatively small in comparison to the growth
inhibition. Distribution of the G2/M phase cells in the
population increase while the percent of apoptotic cells
rose from 3.5% to 10.4%. This is also evident that the G2/
M phase became the dominant phase in cells treated with
5 μg/ml of eurycomanone in a time-dependent manner
with a late apoptosis. These finding indicate that at the
ranges of concentration studied, the antiproliferative
effect of eurycomanone on HepG2 cells could be attrib-
uted primarily to the induction of G2/M arrest, with less
contribution of cell division rather than DNA synthesis.
A flow cytometry results for the DNA content showed
HepG2 cells treated with eurycomanone increased at G2/
M phase compared to the untreated. It was suggested that,
eurycomanone appears to affect processes that are could
inhibit the cell proliferation by inducing G2/M arrest in a
time-dependent manner in HepG2 cells. The G2/M arrest
in HepG2 cells could be induced through up-regulation or
induction of p53. A few researchs have been done towards
the action of several natural products and chemical
against HepG2 cells. Ho and collegues, 2007 [44],
reported that Taiwanin, a lignin isolated from Taiwania
cryptomerioides Hayata, induced cell cycle arrest of HepG2
cells at G2/M phase. Apigenin, a common dietary fla-
vanoid abundantly present in fruits and vegetables also
reported to induce cell cycle arrest of HepG2 cells at G2/
M phase through p53 dependent pathway [31]. Besides,
Shieh et al. 2003 [45] reported that emodin or 1,3,8-trihy-
droxy-6-methyl-anthraquinone displays effective inhibi-
tory effects on the growth of various human hepatoma
cell lines and stimulates the expression of p53 and p21
that resulted in the cell cycle arrest of HepG2/C3A cells at
G2/M phase. The known members of inhibitor of growth
(ING) gene family are considered as candidate tumor sup-
pressor genes, ING4, a novel member of ING family, is
reported to negatively regulate the cell growth with signif-
icant G2/M arrest of cell cycle in HepG2 cells [46].
The studies of the effect of eurycomanone on the expres-
sion of Bcl-2 protein in HepG2 cells shows that eury-
comanone can inhibit Bcl-2 activity, as the time of
exposure increases, the expression of Bcl-2 protein is low-
ered. Bcl-2 is an anti-apoptotis gene that indirectly inhib-
its apoptosis by inhibiting the opening of permeability
transition (PT) channels on the mitochondrian and hence
the lowering of mitochondrial potential [47,48], and by
blocking the release of cytochrome C from mitochon-
drion. As a conclusion from the finding, HepG2 cells are
relatively sensitive to the cytotoxic effect of eurycomanone
which induces apoptosis in HepG2 cells by inhibiting the
Bcl-2 protein. The level of Bax was increased and concom-
itantly that of Bcl-2 was decreased, suggesting that eury-Cancer Cell International 2009, 9:16 http://www.cancerci.com/content/9/1/16
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comanone induced apoptosis through up-regulation of
Bax and down-regulation of Bcl-2 level.
Alterations of the p53 gene are the most frequent genetic
change in human cancers. It is estimated that about 50%
of all human malignancies contain mutations of this gene
[49]. As p53 has been reported to play the role of tran-
scriptional activator, active p53 induces the transcription
of many genes, including many apoptosis-related genes.
The Bax gene has recently been found to be a transcrip-
tional target of p53 and could be up-regulated in response
to a variety of p53-dependent apoptosis triggers [50]. This
present study demonstrates that the up-regulation of Bax
is due to the activated p53. The data also suggest that the
inhibition of cell cycle progression might be associated
with level alterations of the cell cycle related p53. This
finding also suggests that the elevation of p53 expression
may play an important role in eurycomanone induced
G2/M arrest and apoptosis in HepG2 cells. Previous stud-
ies also showed that p53 and p21 are necessary to main-
tain a G2/M arrest and apoptosis following DNA damage
[31].
The activation and action of p53 is believed to be a pivotal
step in the mechanism of apoptosis [51]. Nevertheless,
the effect of p53 on the sensitivity of HepG2 cells to eury-
comanone has not been as extensively studied. Interest-
ingly, from this study, we found that a high level of p53
protein accumulated in the cytoplasm of HepG2 cells.
Many studies have suggested that this protein is a nuclear
protein. There may be a possibility that may cause the
cytoplasmic accumulation of p53. We believed that p53
may act on other pro-apoptotic protiens to modulate their
functions in cytoplasm. p53 may dictate the translocation
of Bax protein from the cytoplasm into mitochondria,
with consequent cytochrome C release [52].
Recent studies show that cytochrome C participates in
activating the programme of cell death. Addition of exog-
enous cytochrome C to cytosol can trigger apoptotic pro-
grammes in a cell-free apoptosis system [53,54], and
microinjection of cytochrome C to cytosol also results in
induction of apoptosis [55]. Since Bax has been seen
shown to be a downstream mediator of p53, it is reasona-
ble to hypothesize that cytochrome C may be involved in
P53-induced apoptosis. As we can see from this experi-
ment, the expression levels of Bax and cytochrome C were
increases, which was supported this hypothesis. In addi-
tion, Bcl-2 may regulate apoptosis by controlling cyto-
chrome C release. Release of cytochrome C in cells
undergoing apoptosis could be prevented by overexpres-
sion of Bcl-2. The inhibitory effect of eurycomanone on
Bcl-2 ultimately leads to an increase in the content of cyto-
chrome C, which directly activates the cascade reaction of
caspase and enhances apoptosis. Increased levels of Bax
protein have been shown to be able to directly induce
release of cytochrome C conceivably by forming a pore in
the outer membrane of mitochondria that allow cyto-
chrome C to leak out [56].
In conclusion, we suggest that, eurycomanone inhibit
cells growth at G2/M phase and prevent cells from
undergo mitosis process. The mechanism of cell death
induce-eurycomanone was via apoptosis. Eurycomanone
enhances apoptosis in HepG2 cell in a p53-dependent
pathway. The large number of p53 expression induces
translocation of Bax from cytoplasm into mitochondrial
which lead to cytochrome C release and induces apoptosis
process to occur. Despite the finding of p53 involvement
in eurycomanone cytotoxicity, the exact downstream tar-
get of p53 is unclear, which require further investigation.
However, we suggest that induction of p53-mediated
apoptosis is, at least in part, a possible explanation for the
anti-liver-carcinogenic effect of eurycomanone, and that
eurycomanone has a potential to prevent cancer.
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